[Allergen-derived peptide: A promising approach in asthma]

Severe asthma required high dose of corticosteroids combined with biotherapies to control more or less asthma symptoms and lead to the decrease of patients' quality of life on long term. Recent studies show that hypoallergenic peptides derived from allergen can prevent airway hyperresponsiveness, decrease Th2 response and also allergen-specific IgE in mouse models of allergic asthma. Even if some peptides mechanisms remain unknown, their fast efficacy with low doses of allergens make peptide immunotherapy a new promising approach in allergic asthma.